B
16.19
-1.60 (-8.99%)
| Penutupan Terdahulu | 17.79 |
| Buka | 17.68 |
| Jumlah Dagangan | 269,532 |
| Purata Dagangan (3B) | 684,038 |
| Modal Pasaran | 718,508,224 |
| Harga / Jualan (P/S) | 73.30 |
| Harga / Buku (P/B) | 2.99 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 May 2026 |
| Margin Operasi (TTM) | -1,133.43% |
| EPS Cair (TTM) | -1.98 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.29% |
| Nisbah Semasa (MRQ) | 13.68 |
| Aliran Tunai Operasi (OCF TTM) | -53.21 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -34.85 M |
| Pulangan Atas Aset (ROA TTM) | -19.54% |
| Pulangan Atas Ekuiti (ROE TTM) | -30.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | BioAge Labs, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.0
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | 1.00 |
|
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. The pipeline Products of the company are NLRP3 inhibitors, APJ against, and others. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| % Dimiliki oleh Orang Dalam | 3.63% |
| % Dimiliki oleh Institusi | 66.65% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Cosmic Management, Llc | 31 Dec 2025 | 501,833 |
| Redpoint Management, Llc | 31 Dec 2025 | 383,254 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 62.00 (Jefferies, 282.95%) | Beli |
| Median | 60.00 (270.60%) | |
| Rendah | 52.00 (Citigroup, 221.19%) | Beli |
| Purata | 58.00 (258.25%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 20.90 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Citigroup | 10 Mar 2026 | 52.00 (221.19%) | Beli | 20.97 |
| Oppenheimer | 25 Feb 2026 | 60.00 (270.60%) | Beli | 22.14 |
| Jefferies | 18 Feb 2026 | 62.00 (282.95%) | Beli | 19.59 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| GOLDSTEIN DOV A MD | - | - | 0 | 0 |
| Jumlah Keseluruhan Kuantiti Bersih | 0 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 0 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| GOLDSTEIN DOV A MD | Pegawai | 23 Apr 2026 | Pelaksanaan pilihan | 3,542 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |